Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Guardant Health (GH) PT Lowered to $130 at Stifel
February 24, 2022 6:57 AM ESTStifel analyst Daniel Arias lowered the price target on Guardant Health (NASDAQ: GH) to $130.00 (from $160.00) while maintaining a Buy rating.
The analyst commented, "GH finished the year with a good beat and an initial 2022 outlook that includes solid clinical volume growth expectations... More
Guardant Health (GH) PT Lowered to $110 at Cowen
February 24, 2022 6:42 AM ESTCowen analyst Max Masucci lowered the price target on Guardant Health (NASDAQ: GH) to $110.00 (from $170.00) while maintaining an Outperform rating.
The analyst commented, "With the ECLIPSE trial readout expected in mid-2022, GH is approaching another landmark event for the field of cancer... More
Guardant Health (GH) Tops Q4 EPS by 46c
February 23, 2022 4:15 PM ESTGuardant Health (NASDAQ: GH) reported Q4 EPS of ($0.69), $0.46 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $108 million versus the consensus estimate of $98.61 million.
GUIDANCE:
Guardant Health sees FY2022 revenue of $460-470 million, versus the consensus of... More
